Skip to content
Science Corporation's PRIMA Implant Shows Promise for Vision Restoration

Science Corporation's PRIMA Implant Shows Promise for Vision Restoration

First seen 17 Oct 2026, 16:47 UTC • •

Article Content

Browse articles
ThreatCluster AI
ThreatCluster •October 18, 2026 at 16:38 UTC
  • •PRIMA implant successfully tested in Stargardt disease patient.
  • •Device combines retinal implant with camera-equipped glasses.
  • •Awaiting FDA clearance after European approval in July 2026.

Science Corporation has successfully implanted its PRIMA vision-restoring chip in a patient with Stargardt disease, a condition leading to central vision loss. The implant, which mimics photoreceptors, is designed to transmit visual information to healthy retinal cells. During rehabilitation, the patient was able to see letters and read words for the first time since losing vision. The PRIMA system combines a retinal implant with camera-equipped glasses, providing a new treatment option for patients with advanced age-related macular degeneration (AMD) and Stargardt disease. The device is currently awaiting FDA clearance in the US after being approved in Europe in July 2026. Approximately 150,000 people worldwide suffer from Stargardt disease, with no current cure available. The device's development marks a significant advancement in brain-computer interface technology, aiming to restore vision by leveraging the body's natural processing capabilities.

Start a free Starter trial for enhanced analysis

Ask AI about this cluster

Updated 28d ago How this analysis works

Timeline

2026-07-01
PRIMA system approved in Europe
The PRIMA vision-restoring chip received regulatory approval in Europe, paving the way for its use in patients with AMD.
Technologyreview
2026-10-13
First patient implanted with PRIMA
Science Corporation announced the successful implantation of the PRIMA chip in a patient with Stargardt disease, marking a significant milestone.
Techcrunch

More articles in this cluster (2)

Common questions

What conditions can the PRIMA implant treat?
The PRIMA implant is designed to treat patients with Stargardt disease and advanced age-related macular degeneration.
How does the PRIMA system work?
The PRIMA system uses a retinal implant that mimics photoreceptors, transmitting visual information to healthy retinal cells via camera-equipped glasses.
What is the current status of the PRIMA implant in the US?
The PRIMA implant is awaiting FDA clearance after receiving approval in Europe.